2I3 Stock Chart & Stats
€4.18
-€0.10(-1.90%)
At close: 4:00 PM EDT
€4.18
-€0.10(-1.90%)
Day’s Range― - ―
52-Week Range€4.06 - €6.75
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€62.46M
Enterprise Value€82.62
Total Cash (Recent Filing)€4.87M
Total Debt (Recent Filing)€4.60M
Price to Earnings (P/E)―
Beta0.55
Next Earnings
Sep 10, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.08
Shares Outstanding13,918,571
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.60
Price to Book (P/B)20.93
Price to Sales (P/S)1.39
P/FCF Ratio-16.37
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.09
Revenue Forecast (FY)€57.38M
Bulls Say, Bears Say
Bulls Say
Core Services GrowthRecord services revenue and strong study conversions indicate durable demand for outsourced oncology research. The PDX Bank differentiation may support repeat customer activity and continued expansion of the core fee-for-service business.
Structural Margin ImprovementBringing radiopharmaceutical activities in-house can permanently reduce reliance on external vendors and improve gross-margin retention. Continued internalization should strengthen unit economics as service volumes scale, provided execution remains effective.
Adjusted Profitability And Low LeverageSustained quarterly adjusted EBITDA positivity marks an improvement in operating discipline and provides evidence that the core model can generate earnings before non-cash and investment items. No debt also reduces financing pressure and interest burden.
Bears Say
Unstable Cash GenerationThe sharp reversal from strong positive cash generation to substantial outflows shows that reported operating progress has not yet translated into dependable cash conversion. This raises funding and execution risk during weaker project or investment cycles.
Data Revenue VolatilityLarge swings in data licensing revenue make the business mix and forecasts less predictable, especially when transactions are sizeable and non-recurring. A broader customer pipeline is encouraging, but durable recurring monetization remains unproven.
Corellia Funding And Liquidity RiskThe budget depends partly on external funding that remains uncertain, creating a risk that Champions Oncology must continue financing Corellia internally. With only modest cash, delayed funding could constrain investment flexibility or require new capital.
Champions Oncology News
2I3 FAQ
What was Champions Oncology Inc’s price range in the past 12 months?
Champions Oncology Inc lowest stock price was €4.06 and its highest was €6.75 in the past 12 months.
What is Champions Oncology Inc’s market cap?
Champions Oncology Inc’s market cap is €62.46M.
When is Champions Oncology Inc’s upcoming earnings report date?
Champions Oncology Inc’s upcoming earnings report date is Sep 10, 2026 which is tomorrow.
How were Champions Oncology Inc’s earnings last quarter?
Champions Oncology Inc released its earnings results on Jul 27, 2026. The company reported €0.009 earnings per share for the quarter.
Is Champions Oncology Inc overvalued?
According to Wall Street analysts Champions Oncology Inc’s price is currently Overvalued.
Does Champions Oncology Inc pay dividends?
Champions Oncology Inc does not currently pay dividends.
What is Champions Oncology Inc’s EPS estimate?
Champions Oncology Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Champions Oncology Inc have?
Champions Oncology Inc has 13,918,571 shares outstanding.
What happened to Champions Oncology Inc’s price movement after its last earnings report?
Champions Oncology Inc reported an EPS of €0.009 in its last earnings report. Following the earnings report the stock price went down -0.943%.
Which hedge fund is a major shareholder of Champions Oncology Inc?
Currently, no hedge funds are holding shares in DE:2I3
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Champions Oncology Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-25.73%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-16.56%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Champions Oncology Inc
Champions Oncology, Inc. is dedicated to developing and commercializing cutting-edge technological products and services designed to personalize cancer treatment and streamline the development of oncology drugs across the United States. At the heart of its offerings is the Tumorgraft Technology Platform, an innovative approach that facilitates individualized cancer care by implanting human tumors into immune-deficient mice. Utilizing this proprietary platform, the company not only delivers personalized cancer solutions directly but also provides Translational Oncology Solutions, supporting pharmaceutical and biotechnology companies through their drug development lifecycle. Additionally, Champions Oncology offers Lumin Bioinformatics, a comprehensive software platform and data tool filled with insights from research services and clinical studies, accessible through annual subscriptions. The company distributes its offerings through various channels, including online platforms, word-of-mouth referrals, and a dedicated sales team, reaching both patients and healthcare professionals. Established in 1985, Champions Oncology, Inc. is based in Hackensack, New Jersey, and was formerly known as Champions Biotechnology, Inc. until its name change in April 2011.
2I3 Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a generally positive operational and financial trajectory: record annual revenue, strong services growth (+12%), sustained positive adjusted EBITDA across all quarters, and margin improvement tied to in‑sourcing radiopharma work. Key negatives centered on a large year-over-year decline in data license revenue (~83% drop) driven by the non-recurrence of a one-time large deal, quarter-to-quarter data revenue volatility, a GAAP net loss due to investments, and uncertainty around Corellia funding. On balance, the positives around core services performance, profitability on an adjusted basis, margin progress, and pipeline/customer expansion in data outweigh the near-term data revenue volatility and funding uncertainties.View all DE:2I3 earnings summariesTechnical Analysis
Oncolytics Biotech
―
―
Cardiff Oncology
―
MaxCyte
―
Black Diamond Therapeutics
―
Lantern Pharma
―